Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Indication assessment · §3

Delayed gastric emptying and gastrointestinal motility effects — trial records

Trial records in the Institute's register bearing on delayed gastric emptying and gastrointestinal motility effects.

Document identifier
CEI-IN-19/3
Series
Indication assessment
Version
2.3
Published
23 Apr 2024
Last reviewed
23 Apr 2024
Next review
23 Apr 2026
Identifier
10.71829/cei.ind.19
Certainty
Not rated
Cycle
2024 Q2
ICD-11
DA91.3
Category
Gastrointestinal

§3Trials in this indication

6 trial records in the Institute's register bear on this indication, of which 1 is a published trial.

Table 2. Trial records bearing on delayed gastric emptying and gastrointestinal motility effects.

RecordCompoundPhaseDesignRandomisedYear
IPA-PH2-POIIpamorelinPhase 2Randomised, double-blind, placebo-controlled2011
IPA-PH2-POI-ADHERENCEprogramme recordIpamorelinPhase 2Observational2011
IPA-PH2-POI-BIOMARKERprogramme recordIpamorelinPhase 2Randomised, double-blind, placebo-controlled2011
IPA-PH2-POI-ELDERLYprogramme recordIpamorelinPhase 2Randomised, double-blind, placebo-controlled2011
IPA-PH2-POI-OLEprogramme recordIpamorelinPhase 2Single-arm open-label2011
IPA-PH2-POI-PKprogramme recordIpamorelinPhase 1Phase 1 ascending dose2011
This facet in the trial register.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine 2017;377(13):1228–1239. doi:10.1056/NEJMoa1612917 · PMID 28910237

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.